Glenmark Pharma gains on receiving USFDA’s nod for Icatibant Injection

24 May 2021 Evaluate

Glenmark Pharma is currently trading at Rs. 616.70, up by 9.35 points or 1.54% from its previous closing of Rs. 607.35 on the BSE.

The scrip opened at Rs. 612.00 and has touched a high and low of Rs. 619.15 and Rs. 609.20 respectively. So far 59452 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 640.30 on 12-May-2021 and a 52 week low of Rs. 341.60 on 28-May-2020.

Last one week high and low of the scrip stood at Rs. 624.00 and Rs. 599.20 respectively. The current market cap of the company is Rs. 17435.17 crore.

The promoters holding in the company stood at 46.63%, while Institutions and Non-Institutions held 35.00% and 18.38% respectively.

Glenmark Pharmaceuticals has received final approval by the United States Food & Drug Administration (USFDA) for Icatibant Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe, the generic version of Firazyr Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe, of Shire Human Genetic Therapies, Inc. This marks Glenmark’s first synthetic decapeptide injectable approval and will be manufactured in their North American manufacturing facility based in Monroe, North Carolina.

According to IQVIATM sales data for the 12 month period ending March 2021, the Firazyr Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe market achieved annual sales of approximately $223.4 million.

Glenmark’s current portfolio consists of 172 products authorized for distribution in the U.S. marketplace and 44 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

1938.35 19.30 (1.01%)
09-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1776.20
Dr. Reddys Lab 1246.25
Cipla 1490.70
Zydus Lifesciences 919.90
Lupin 2052.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×